MedPath

Dextran

Generic Name
Dextran
Brand Names
Bion Tears, Colirio Ocusan, Genteal Tears, Genteal Tears Mild, Tears Naturale, Tears Renewed
Drug Type
Small Molecule
CAS Number
9004-54-0
Background

Dextran is a polysaccharide that differs from others in that its glucose units are joined together 1:6 glucoside links. The main chain of glucose has short branches at frequent intervals which are probably joined by 1:3 and 1:4 glucoside links. The chains can be composed of about 200,000 glucose units. Many bacteria, like Leuconostoc, can synthesize dextran from sucrose, and this activity is used commercially to obtain dextran.

Dextran 40 is a sterile, nonpyrogenic preparation of low molecular weight dextran (average mol. wt. 40,000) in 5% Dextrose Injection or 0.9% Sodium Chloride Injection. It is administered by intravenous infusion.

Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. It is produced from certain bacteria that with α-1,6 glycosidic linkages between glucose molecules and α-1,3 linkages between branches. When labelled with technetium Tc99m, dextran 75 is intravenously administered as an imaging agent to detect and diagnose conditions in the vascular compartment such as pericardial effusion or ventricular aneurysm.

Indication

Dextran is used as the restoration of blood mass during surgical interventions if there is hypovolemia due to trauma or dehydration. It is as well used after the presence of hemorrhage in cases of blood loss to a level inferior to 15% of the blood mass, if compatibility test cannot be completed or when blood lots need to be tested for pathogen detection. Dextran is also used for the prevention of profound postoperative venous thrombosis.

Dextran as well presents ophthalmic applications as solutions or ointments for the temporary relief of xerophthalmia or minor ocular irritations.

Associated Conditions
Blood Circulation Disorder, Capillary disorder, Dry Eyes, Ocular Irritation, Pulmonary Embolism, Pulmonary Embolism caused by procedures associated with a high incidence of thromboembolic complications, Shock, Thrombosis, Venous Thrombosis (Disorder), Venous Thrombosis caused by procedures associated with a high incidence of thromboembolic complications
Associated Therapies
Plasma Volume Replacement, Priming fluid in pump oxygenators therapy

Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study

Conditions
Type 2 Diabetes
Diabetic Nephropathies
Adolescent Obesity
Diabetic Kidney Disease
Nephropathy
Obesity
Diabetes Type 2
Interventions
Procedure: Renal Biopsy
Radiation: Positron Emission Tomography
First Posted Date
2022-09-07
Last Posted Date
2022-11-02
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
100
Registration Number
NCT05530356
Locations
🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

Phase 4
Completed
Conditions
Allergic Conjunctivitis
Interventions
First Posted Date
2022-04-06
Last Posted Date
2022-09-02
Lead Sponsor
Andover Research Eye Institute
Target Recruit Count
61
Registration Number
NCT05314621
Locations
🇺🇸

Andover Eye Associates, Andover, Massachusetts, United States

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

Phase 4
Completed
Conditions
Allergic Conjunctivitis
Interventions
First Posted Date
2022-03-04
Last Posted Date
2022-05-03
Lead Sponsor
Andover Research Eye Institute
Target Recruit Count
58
Registration Number
NCT05265910
Locations
🇺🇸

Andover Eye Associates, Andover, Massachusetts, United States

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

Recruiting
Conditions
Diabetic Kidney Disease
Adolescent Obesity
Kidney Hypoxia
Puberty
Type 2 Diabetes Mellitus
Pre Diabetes
Interventions
First Posted Date
2021-08-17
Last Posted Date
2025-03-24
Lead Sponsor
Petter Bjornstad
Target Recruit Count
100
Registration Number
NCT05008276
Locations
🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction

Not Applicable
Conditions
Meibomian Gland Dysfunction
Sjögren's Syndrome
Interventions
First Posted Date
2018-02-15
Last Posted Date
2018-02-15
Lead Sponsor
LanZhou University
Target Recruit Count
60
Registration Number
NCT03434106
Locations
🇨🇳

Lanzhou University Second Hospital, Lanzhou, Gansu, China

Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome

Not Applicable
Completed
Conditions
Liposic
Tear Film
Dry Eye
Lipid Layer
Tears Naturale Forte
Interventions
First Posted Date
2017-07-07
Last Posted Date
2018-02-26
Lead Sponsor
Huaxia Eye Hospital Group
Target Recruit Count
95
Registration Number
NCT03211351
Locations
🇨🇳

Huaxia Eye Hosptial of Foshan, Foshan, Guangdong, China

Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury

Phase 2
Completed
Conditions
Cirrhosis, Liver
AKI
Interventions
First Posted Date
2017-03-03
Last Posted Date
2017-03-03
Lead Sponsor
Ramathibodi Hospital
Target Recruit Count
10
Registration Number
NCT03070353

Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?

Not Applicable
Conditions
Sjögren's Syndrome
Meibomian Gland Dysfunction
Interventions
First Posted Date
2017-02-23
Last Posted Date
2017-05-16
Lead Sponsor
Tung Wah Hospital
Target Recruit Count
80
Registration Number
NCT03060005
Locations
🇨🇳

Tungwah Hospital of Sun Yat-sen University, Dongguan, Guangdong, China

Comparison of the Clinical Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome

Not Applicable
Conditions
Dry Eye
Interventions
First Posted Date
2016-12-14
Last Posted Date
2016-12-15
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
50
Registration Number
NCT02992392
Locations
🇨🇳

Hainan Eye Hospital, Zhongshan Ophthalmic Center of Sun Yat-sen University, Haikou, Hainan, China

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

Phase 1
Completed
Conditions
Keratolysis
Interventions
Device: UVA Light Source
First Posted Date
2016-08-11
Last Posted Date
2023-05-10
Lead Sponsor
Joseph B. Ciolino, MD
Target Recruit Count
76
Registration Number
NCT02863809
Locations
🇺🇸

UC Davis Health System Eye Center, Sacramento, California, United States

🇺🇸

The Jules Stein Eye Institute, Los Angeles, California, United States

🇺🇸

Shiley Eye Institute, University of California, San Diego, San Diego, California, United States

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath